Naveglitazar

DB12662InvestigationalSmall molecule

Naveglitazar has been used in trials studying the treatment of Diabetes Mellitus, Non-Insulin-Dependent.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor alpha and Peroxisome proliferator-activated receptor gamma
Curator reviewed
Formula / weight: C₂₅H₂₆O₆ · 422.477 g/mol (avg)
Code names: LY-519818 · LY-9818

Resolves to

Compound

Structure

InChIKeyOKJHGOPITGTTIM-DEOSSOPVSA-NSMILESCO[C@@H](CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1)C(O)=O

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

16+ReferencesStructured and connected to the statements they support

Which drugs share a target with Naveglitazar, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.